viewCellmid Limited

Cellmid subsidiary Advangen International enters into agreement with K2B Co Ltd for distribution of évolis products

Avangen is engaged in the development and sale of clinically validated anti-ageing products for skin, hair and body.

Cellmid Ltd - Cellmid subsidiary Advangen International enters into agreement with K2B Co Ltd for distribution of évolis products

Cellmid Ltd (ASX:CDY) wholly owned subsidiary Advangen International Pty Ltd has entered into an exclusive agreement with K2B Co Ltd (K2B) for the distribution of its évolis anti-ageing hair care and hair loss products in the Republic of Korea.

The agreement is a major step in delivering on the company’s Asian expansion plans, with the product launch expected in Q4 FY 2020 following registration with the Korean Ministry of Food and Drug Safety.

K2B will primarily use television shopping and e-commerce for the sale of the évolis products, consistent with Cellmid’s objective to increase its direct-to-consumer-business and customer base globally.

READ: Cellmid’s Japanese shopping channel sale sets revenue record of $1.14 million

Cellmid chief executive officer Maria Halasz said: “K2B’s direct-to-consumer model is ideally suited the évolis products and we are excited to partner with their team in this major market for hair growth products.”

K2B, a company that specialises in marketing through television shopping with relationships in the Korean healthcare sector, has conducted research demonstrating the Korean hair-loss market valued at US$3.69 billion in 2017.

READ: Cellmid MD and CEO demonstrate confidence through further on-market share purchase

The agreement between the companies has the following key terms:

The term of the agreement will be three years, extendable by another two years subject to meeting minimum order requirements;

Minimum order requirements will begin in the first year and are expected to increase over the subsequent two years;

The company’s évolis branded Australian manufactured products for men and women are included in the agreement;

The products will be positioned in the premium category and pricing will be consistent with Australian product pricing;

Responsibility for marketing of the products within the territory falls exclusively to K2B, with a prescribed minimum advertising spend set as a percentage of the orders; and

Advangen will provide support in the form of product training, videos, imagery and assistance with generating on-brand marketing collateral.

Quick facts: Cellmid Limited

Price: 0.1 AUD

Market: ASX
Market Cap: $12.52 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cellmid Limited named herein, including the promotion by the Company of Cellmid Limited in any Content on the Site, the Company receives from...


Cellmid Limited to supply rapid diagnostic tests to help in new pandemic

Cellmid Limited (ASX:CDY) CEO Maria Halasz tells Proactive's Andrew Scott they've signed an agreement to supply rapid diagnostic tests (RDT), with products expected to arrive in the country by early April. The test uses a virus-specific detection method that delivers results anywhere between...

on 30/3/20

2 min read